Yet, as PHOX2B expression levels vary between tumors, we further showed that adding other markers, tyrosine hydroxylase (TH), dopamine decarboxylase (DDC), cholinergic receptor nicotinic alpha 3 (CHRNA3), and growth associated protein 43 (GAP43), contributes to more sensitive MRD detection [21, 22] and the clinical utility for patients with neuroblastoma of all risk groups [15, 23, 24]. The gene discussed is CHRNA3; the disease is neuroblastoma.